Inclusion Criteria:  Males and females admitted to subacute and long-term skilled nursing care facilities. Known history of T2D treated with insulin (glargine, detemir, degludec, NPH, premixed insulin) or sliding scale regular insulin) or insulin secretagogues (sulfonylureas, repaglinide, nateglinide) with or without additional oral antidiabetic agents (alpha-glucosidase inhibitors, thiazolidinedione, SGLT2- inhibitors, DPP4-inhibitors), short- and long-acting GLP1-RA (exenatide, liraglutide, dulaglutide, semaglutide). Patients with an expected LTC length-of-stay > 1 week.  Exclusion Criteria:  Patients expected to require MRI procedures during admission. Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or anasarca (massive peripheral edema). Female subjects who are pregnant or breast-feeding at time of enrollment into the study.